Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 158,528 shares of the company’s stock after acquiring an additional 1,504 shares during the period. The Manufacturers Life Insurance Company’s holdings in Vaxcyte were worth $12,977,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PCVX. Vanguard Group Inc. grew its position in shares of Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock valued at $979,184,000 after acquiring an additional 521,204 shares during the period. Capital Research Global Investors boosted its position in Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after purchasing an additional 1,312,302 shares in the last quarter. Franklin Resources Inc. boosted its position in Vaxcyte by 3.0% during the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company’s stock worth $234,884,000 after purchasing an additional 82,997 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Vaxcyte by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company’s stock valued at $229,495,000 after buying an additional 102,106 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Vaxcyte by 8.1% in the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company’s stock valued at $145,659,000 after buying an additional 133,448 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on PCVX shares. The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They set an “overweight” rating for the company. Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Finally, Bank of America reduced their target price on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Price Performance

PCVX opened at $35.39 on Friday. The firm has a market capitalization of $4.56 billion, a price-to-earnings ratio of -7.69 and a beta of 1.26. The company’s 50 day simple moving average is $50.92 and its two-hundred day simple moving average is $77.35. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 24,000 shares of company stock worth $1,946,720 in the last quarter. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.